784. Activity of Eravacycline Against Anaerobic Bacteria from Europe Collected in 2013-14
Session: Poster Abstract Session: Antimicrobial Agents: Novel Agents
Friday, October 9, 2015
Room: Poster Hall
Posters
  • IDWeek2015_Eravacycline in vitro activity_Anaerobes_FINAL.pdf (174.4 kB)
  • Background: Eravacycline is a novel, fully synthetic fluorocycline antibiotic with broad-spectrum activity available in intravenous and oral formulations for the treatment of multidrug-resistant (MDR) infections. Eravacycline has recently completed two Phase 3 studies for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). The current study assessed the activity of eravacycline against 1,079 anaerobic bacteria collected from European hospitals in 2013-2014.

    Methods: A total of 1,079 clinical anaerobic isolates from Europe were tested. MICs were determined by agar dilution according to CLSI guidelines. Quality control testing was performed on each day of testing as specified by the CLSI.

    Results : Eravacycline results (in g/ml) for all anaerobes combined and major species collected (where N≥30) are shown in the following Table:

    Organism/MIC (g/ml)

    N

    MIC50

    MIC90

    MIN

    MAX

    All anaerobes

    1,079

    0.12

    1

    0.004

    8

    Bacteroides fragilis

    198

    0.25

    2

    0.06

    8

    Clostridium difficile

    117

    0.03

    0.06

    0.004

    0.5

    Finegoldia magna

    84

    0.06

    0.12

    0.015

    0.25

    Clostridium perfringens

    76

    0.06

    0.5

    0.015

    2

    Bacteroides thetaiotaomicron

    62

    0.5

    2

    0.03

    8

    Prevotella bivia

    62

    0.25

    1

    0.06

    4

    Parvimonas micra

    56

    0.008

    0.03

    0.008

    0.12

    Peptostreptococcus anaerobius

    51

    0.03

    0.06

    0.015

    0.5

    Bacteroides ovatus

    35

    0.25

    1

    0.03

    2

    Bacteroidesvulgatus

    34

    0.25

    1

    0.03

    2

    Peptoniphilus harei

    31

    0.03

    0.06

    0.004

    0.12

    MIN, minimum MIC; MAX, maximum MIC

    Conclusion: Eravacycline was very active against anaerobic bacteria collected from Europe MIC90 ranged from 0.03 - 2 g/ml. Overall, eravacycline showed promising activity and data from the Phase 3 trials will be used in determining the clinical breakpoints.

    Ian Morrissey, PhD1, Joyce Sutcliffe, PhD2, Meredith Hackel, PhD, MPH3 and Stephen Hawser, PhD1, (1)IHMA Europe Srl, Epalinges, Switzerland, (2)Biology, Tetraphase Pharmaceuticals, Inc., Watertown, MA, (3)International Health Management Associates, Inc., Schaumburg, IL

    Disclosures:

    I. Morrissey, IHMA Europe Srl: Independent Contractor , Consulting fee

    J. Sutcliffe, Tetraphase Pharmaceuticals: Employee , Salary

    M. Hackel, IHMA, Inc.: Independent Contractor , Consulting fee

    S. Hawser, IHMA Europe Srl: Independent Contractor , Consulting fee

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.